The four chemotherapy regimens evaluated in Eastern Cooperative Oncology Group study 1594 (paclitaxel/cisplatin, gemcitabine/cisplatin, docetaxel/cisplatin, and paclitaxel/carboplatin) are effective treatment options for the therapy of advanced non鈥搒mall-cell lung cancer (NSCLC). Only numerical differences...
Toward personalized treatment approaches for non-small-cell lung cancer Article 12 August 2021 Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany Article Open access 11 July 2024 The current treatment landscape in the UK for stage III NSCL...
Overview Risks Symptoms Diagnosis Treatment Management What is non-small cell lung cancer?Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually ...
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current tre...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
This vinblastine/very high-dose cisplatin regimen showed minor activity against non-small-cell lung cancer. The level of activity did not surpass that of standard-dose (100 mg/m2 per cycle) cisplatin-containing regimens. This is a preview of subscription content, log in via an institution to ...
Non-small cell lung cancer (NSCLC) is the main subtype of lung cancer, andpemetrexed(PEM) resistance limits its treatment[20]. Multiple studies showed thatHDAC1, which can regulate H3K18cr in cancer development, was upregulated in clinical NSCLC tissues and correlated with poor pro...
Hyperfractionated/accelerated radiotherapy regimens for the treatment of non-small cell lung cancer: a systematic review of clinical and cost-effectiveness Background• This systematic review was undertaken to address a regional policy question regarding the clinical effectiveness and cost-effectiveness of...
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring ... Phase II study of a combina- tion regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease characterized by a broad spectrum of oncogenic driver alterations. Currently, targeted therapies are the standard treatment for most oncogene-driven patients [1]. However, not all oncogenic drivers, such as human epidermal growth factor ...